Although they found no association between the CHEK2 mutation status and early diagnosis or PrC, they noted that c.1100delC mutation carriers are more prevalent among patients with a lethal disease than in patients with low-risk prostate cancer (1.28% vs. 0.16%; p = 0.004). This evidence concerns the gene CHEK2 and prostate cancer.